abt-510
Peptideexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2003 (NCT00061646)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN(C)C(C)=O)C(C)C)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC)[C@@H](C)CC- Mol. weight
- 994.25 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL386115 ↗
Also known as
- abt510
- abt 510
- abt 510
- abt 510
- abt-510
- abt-510
- abt-510
- abt-510
- n-acetyl-sarcosyl-glycyl-valyl-alloisoleucyl-threonyl-norvalyl-isoleucyl-arginyl-proline ethylamide
- nac-sar-gly-val-(d-allo-ile)-thr-nva-ile-arg-pronet
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00113334 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2005 | Abbott, University of Texas at Houston |
| NCT00602199 | Phase 2 | Nov 1, 2004 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00584883 | Phase 1 | Aug 1, 2003 | University of Alabama, Birmingham |
| NCT00073125 | Phase 2 | May 1, 2003 | Abbott |
| NCT00061659 | Phase 2 | May 1, 2003 | Abbott |
| NCT00061672 | Phase 2 | Apr 1, 2003 | Abbott |
| NCT00061646 | Phase 2 | Mar 1, 2003 | Abbott |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbott | For profit | 5 | 4 | 1 | 2003 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2004 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2004 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2003 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2005 |
5 organizations
Page 1 / 1